Skip to main content
Theradiag logo

Theradiag — Investor Relations & Filings

Ticker · ALTER ISIN · FR00140069U4 LEI · 969500CDG241WHIFL611 PA Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2017-12-21 Regulatory Filings
Country FR France
Listing PA ALTER

About Theradiag

https://www.theradiag.com/en/home-2/

Theradiag is a company that develops, manufactures, and markets in-vitro diagnostic (IVD) solutions, with a primary focus on theranostics. The company specializes in creating tools for monitoring biotherapies, which are treatments using substances derived from living organisms. Its core product line, Lisa-Tracker, is a range of kits designed to help clinicians measure the efficacy of biotherapies, particularly for patients with autoimmune diseases. This allows for the personalization of treatment and improved patient outcomes. In addition to its focus on biotherapy monitoring, Theradiag also maintains its activities in developing and distributing diagnostic tests for autoimmunity and oncogenetics. The company leverages its extensive experience to provide innovative diagnostic tools for clinicians and patients.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 95% confidence The document is a press release dated December 21, 2017, announcing that THERADIAG signed a partnership agreement with MSD France for monitoring Remicade® using LISA TRACKER® kits. This type of announcement, detailing a specific business development, partnership, or contract signing, does not fit the definitions for formal financial reports (10-K, IR, ER, MRQ), governance documents (DEF 14A, CGR), or shareholder actions (AGM-R, DVA). It is a material event disclosure. Since it is not a standard regulatory filing like a 10-K or a specific financial update, and it is not a general regulatory announcement (RNS), the most appropriate category for a specific business development announcement that doesn't fit elsewhere is often considered a Regulatory Filing (RNS) if it's a mandatory disclosure, or sometimes it falls under a general 'Other' category. Given the provided list, and recognizing this as a significant, non-financial-results-focused corporate event announcement, it is best classified as a general Regulatory Filing (RNS) as it serves as a public disclosure of a material event, or potentially a Legal/Transaction related filing if it were M&A (TAR). Since it is a partnership agreement, and not a merger/takeover (TAR), RNS is the best fit as a general disclosure mechanism for material news not covered by other specific codes.
2017-12-21 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 98% confidence The document is titled "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references the French Commercial Code and the AMF (Autorité des Marchés Financiers) regulations. The core content is a table showing the total number of shares and voting rights as of a specific date (November 30, 2017). This type of mandatory disclosure regarding the total share count and voting power directly corresponds to announcements about capital structure changes or share issuance/status updates. Given the options, 'Share Issue/Capital Change' (SHA) is the most appropriate fit, as it relates to the official count of shares outstanding, which is a fundamental aspect of the capital structure. It is not a general earnings release (ER), a full annual report (10-K), or a director's dealing (DIRS).
2017-12-01 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 95% confidence The document is a press release dated November 14, 2017, announcing a partnership agreement between Theradiag and Biogen regarding the supply of LISA TRACKER monitoring kits for Flixabi®. This announcement details a strategic business development, specifically a commercial agreement, rather than a mandatory regulatory filing like a 10-K, an earnings report, or a change in management. It does not fit the definitions for AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, FS, CGR, IRAT, IR, IP, LTR, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS. It is a specific corporate announcement. Since it is not a standard regulatory filing (like 10-K or IR) and doesn't fit the other specific categories, the most appropriate classification is the general Regulatory Filings category (RNS), which serves as a fallback for miscellaneous corporate announcements that are not covered by the more specific types, although 'TAR' (M&A Activity) is sometimes used for major commercial deals, this is strictly a partnership/supply agreement, making RNS the safer general classification for non-standard corporate news releases.
2017-11-14 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document announces a partnership agreement between THERADIAG and BIOGEN regarding the supply of LISA TRACKER monitoring kits for Flixabi®. This is a specific corporate announcement detailing a business development, partnership, or strategic agreement. It is not a standard periodic financial report (10-K, IR, ER, MRQ), a formal regulatory filing like a proxy statement (DEF 14A), or a transcript (CT). It fits best under a general corporate action or announcement category. Since there is no specific 'Partnership Announcement' code, and it details a significant business development, it is most appropriately classified as a Regulatory Filing (RNS) as a general announcement that doesn't fit the highly specific financial/governance categories, or potentially a general Corporate Information/Announcement if one existed. Given the provided list, RNS serves as the best general regulatory/corporate announcement fallback for non-standard disclosures like this partnership agreement.
2017-11-14 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 98% confidence The document is titled "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly provides a table detailing the total number of shares and theoretical voting rights as of October 31, 2017, referencing French commercial code and AMF regulations. This type of mandatory disclosure regarding the total share count and voting rights directly corresponds to announcements about capital structure changes or share issuance/status. Among the provided definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate fit, as the document reports the current state of the total share capital and voting rights, which is a fundamental aspect of capital structure reporting. It is not a general earnings release (ER), an interim report (IR), or a director's dealing (DIRS).
2017-11-02 French
Rapport financier semestriel
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL' (Interim Financial Report) for the first half of 2017. It contains a declaration by the responsible person, details on board composition, a management report on activities, and consolidated financial statements (balance sheet/income statement data). It is a comprehensive report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2017
2017-10-17 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.